Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma. Although in the majority of patients the condition responds well to first-line immunochemotherapy combinations containing rituximab, 10 to 15% have primary refractory disease within 3 months after treatment initiation,…

http://bit.ly/2BZLa5L